Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR Database [0.03%]
来自DLL3 PanTUMOR数据库的广泛期小细胞肺癌患者在接受Tarlatamab联合放疗后的结局分析
Diana Kim,Sarah Blocker,Courtney C Cavalieri et al.
Diana Kim et al.
Background: Small cell lung cancer (SCLC) is an aggressive malignancy in which radiotherapy remains integral across both limited and extensive stages (ES-SCLC). Tarlatamab has shown improved survival versus chemotherapy a...
Thoracic Radiotherapy and Radiation Time Would Affect the Efficacy of Advanced Non-Small Cell Lung Cancer for Patients Who Responded to TKIs Treatment [0.03%]
胸部放疗和照射时间会影响TKI治疗有效的晚期非小细胞肺癌患者的疗效
Ma Jinbo,Li Cheng,Wang Xiao et al.
Ma Jinbo et al.
Purpose: This trial aimed to investigate the difference in treatment efficacy of thoracic radiotherapy before and after thoracic progression during treatment with EGFR-TKI to determine the optimal timing of consolidation ...
First Frameshift Mutation of ALK in Non-Small Cell Lung Cancer Remaining Sensitive to Alectinib: Case Report [0.03%]
ALK第一个移码突变的非小细胞肺癌患者对艾乐替尼敏感：病例报告
Xiaoqian Zhai,Zuoyu Liang,Cheng Zhen et al.
Xiaoqian Zhai et al.
Limited-Stage Small-Cell Lung Cancer With Severe Paraneoplastic Limbic Encephalitis Successfully Treated With Chemoradiotherapy Followed by Immune Checkpoint Inhibitor Maintenance Therapy: A Case Report [0.03%]
限局期小细胞肺癌伴重度副肿瘤性边缘叶脑炎成功序贯化放免疫维持治疗一例
Daisuke Morinaga,Hidenori Kitai,Hanko Sato et al.
Daisuke Morinaga et al.
Amivantamab-Associated Vasculitis in a Patient With EGFR Exon 20 Insertion Non-Small Cell Lung Cancer: A Case Report [0.03%]
含EGFR 20号外显子插入突变的非小细胞肺癌患者使用安维替尼治疗后出现血管炎：病例报告
Daisuke Morinaga,Megumi Furuta,Doppo Fukui et al.
Daisuke Morinaga et al.
Factors Influencing Refusal of Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma [0.03%]
影响非小细胞肺癌患者拒绝辅助化疗的因素分析
Claire Perez,Vikram Krishna,Drew Bolster et al.
Claire Perez et al.
Background: Adjuvant chemotherapy is recommended for patients with resectable stage II and IIIA non-small cell lung cancer (NSCLC) and may be considered for high-risk stage I cases. Despite these guidelines, a significant...
When Timing is Everything: Rethinking Immunotherapy Integration With Definitive Chemoradiation [0.03%]
当时间至关重要时：重新思考免疫治疗与根治性放化疗联合应用的最佳时机
Parth A Desai,Martin J Edelman
Parth A Desai
Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England [0.03%]
一线免疫单药或联合培美曲塞维持治疗非鳞状NSCLC患者（无靶向突变）的疗效分析：英格兰真实世界研究
Fabio Gomes,Niall Gilding,Vivian Tan et al.
Fabio Gomes et al.
Objectives: Real-world analyses of first-line maintenance (1LM) immuno-oncology (IO) treatment with or without pemetrexed for patients with non-squamous (NSQ) advanced/metastatic non-small cell cancer (a/mNSCLC), includin...
A Randomized Phase II Trial of Hypo-fractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction Versus Standard- Fractionated IMRT, Concurrent With Carboplatin/Paclitaxel and Followed by Consolidation Durvalumab, for Subjects With Stage III Non-Small Cell Lung Cancer [0.03%]
一项关于III期非小细胞肺癌患者的随机II期试验，评估 hypo-fractionated 照射强度调制放射治疗（IMRT）联合卡铂/紫杉醇方案与标准分割IMRT的疗效，并在IMRT后使用durvalumab进行巩固治疗
Krishna Reddy,Fen Wang,Ying Cao et al.
Krishna Reddy et al.
Background: Locoregional control remains suboptimal for patients with stage III non-small cell lung cancer (NSCLC) who receive standard-of-care concurrent chemoradiation, with standard-fractionated radiation treatment (RT...
Management of Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC): An Updated Review [0.03%]
肺大细胞神经内分泌癌(LCNEC)的诊疗进展（篇前语：更新回顾）
Anson Man Lok Yeung,James Chung Hang Chow
Anson Man Lok Yeung
Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is an uncommon and aggressive malignancy, accounting for approximately 3% of all primary lung malignancies. Due to its rarity, the treatment paradigm for LCNEC is primarily derived from ...